Patent · US Active

T cell receptors and immune therapy using the same against PRAME positive cancers

US11111286B2 · kind B2 · utility

1Cited by

0References

20Claims

0Family size

Assignee

Immatics Biotechnologies GmbH · DE

Inventors

Leonie ALTEN · Lörrach, DE
Dominik MAURER · Lingen (Ems), DE
Sebastian BUNK · Wien, AT
Claudia WAGNER · Lörrach, DE
Mathias Ferber · Paris, FR

Key dates

Filing date	Dec 31, 2019
Grant date	Sep 7, 2021
Priority date	—
Expiry date	Dec 31, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular against Preferentially Expressed Antigen of Melanoma (PRAME). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.